
HNGE Stock Forecast & Price Target
HNGE Analyst Ratings
Bulls say
Hinge Health is well-positioned for success with its innovative technology platform addressing the growing demand for MSK pain treatment. Along with introducing new products, the company is focused on expanding its market reach and gaining FDA clearance for its migraine treatment. This, along with their commitment to quality care and partnerships with providers, makes Hinge Health a strong investment opportunity with the potential for significant revenue growth.
Bears say
Hinge Health is a digital healthcare company leveraging AI technology to automate care for joint and muscle health, with little expected financial impact until 2027. The company's new product, HingeSelect, is poised to improve overall yield by capturing additional musculoskeletal spend, and management is optimistic that AI tools and operating discipline will drive efficiency gains. However, the company's operating margin target does not rely on pricing or ASP expansion, and the majority of migraine utilization data is not expected until next year, suggesting limited short-term growth potential for investors.
This aggregate rating is based on analysts' research of Hinge Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HNGE Analyst Forecast & Price Prediction
Start investing in HNGE
Order type
Buy in
Order amount
Est. shares
0 shares